TRCT
STRO icon

Tower Research Capital (TRC)’s Sutro Biopharma STRO Stock Holding History

Tower Research Capital (TRC)’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8K Buy
+866
New +$27K ﹤0.01% 3220
2025
Q4 		– Sell
-2,402
Closed -$20.9K – 5584
2025
Q3 		$20.9K Sell
2,402
-86
-3% -$732 ﹤0.01% 3273
2025
Q2 		$17.8K Buy
2,488
+1,117
+81% +$9.13K ﹤0.01% 3744
2025
Q1 		$8.92K Buy
1,371
+600
+78% +$9.45K ﹤0.01% 3841
2024
Q4 		$14.2K Buy
771
+403
+110% +$12.3K ﹤0.01% 3472
2024
Q3 		$12.7K Sell
368
-820
-69% -$32.1K ﹤0.01% 3565
2024
Q2 		$34.8K Buy
1,188
+726
+157% +$28.7K ﹤0.01% 3373
2024
Q1 		$26.1K Sell
462
-478
-51% -$21.1K ﹤0.01% 2767
2023
Q4 		$40.3K Sell
940
-573
-38% -$18.2K ﹤0.01% 3272
2023
Q3 		$52.5K Buy
1,513
+1,171
+342% +$51K ﹤0.01% 2509
2023
Q2 		$15.9K Buy
342
+25
+8% +$1.24K ﹤0.01% 3600
2023
Q1 		$15K Buy
317
+183
+137% +$11.6K ﹤0.01% 3815
2022
Q4 		$11K Sell
134
-191
-59% -$13.3K ﹤0.01% 3869
2022
Q3 		$18K Sell
325
-245
-43% -$14.5K ﹤0.01% 4024
2022
Q2 		$30K Buy
570
+447
+363% +$25K ﹤0.01% 3386
2022
Q1 		$10K Sell
123
-421
-77% -$40.1K ﹤0.01% 4348
2021
Q4 		$81K Buy
544
+242
+80% +$43.4K ﹤0.01% 2377
2021
Q3 		$57K Sell
302
-42
-12% -$7.99K ﹤0.01% 2847
2021
Q2 		$64K Sell
344
-12
-3% -$2.35K ﹤0.01% 2813
2021
Q1 		$81K Buy
356
+147
+70% +$34.9K ﹤0.01% 2752
2020
Q4 		$45K Sell
209
-1,633
-89% -$270K ﹤0.01% 3219
2020
Q3 		$185K Buy
1,842
+1,154
+168% +$109K ﹤0.01% 2649
2020
Q2 		$53K Buy
+688
New +$66K ﹤0.01% 3001
2019
Q4 		– Sell
-11
Closed -$1K – 4318
2019
Q3 		$1K Sell
11
-109
-91% -$11K ﹤0.01% 3922
2019
Q2 		$14K Buy
120
+97
+422% +$10.7K ﹤0.01% 2380
2019
Q1 		$3K Sell
23
-529
-96% -$55K ﹤0.01% 3321
2018
Q4 		$49K Buy
+552
New +$66.6K ﹤0.01% 1299

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Tower Research Capital (TRC)'s STRO Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Sutro Biopharma (STRO) in Q2 2026: 866 shares worth $28.8K. The stake represents ﹤0.01% of the portfolio and ranks #3220 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in STRO as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in STRO in Q4 2018 and has held it in 27 quarters since. The position peaked at $185K in Q3 2020. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Tower Research Capital (TRC) held 866 shares of Sutro Biopharma worth $28.8K as of Q2 2026.
  • Sutro Biopharma was a new Tower Research Capital (TRC) position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3220 holding.
  • Tower Research Capital (TRC) first reported a position in Sutro Biopharma in Q4 2018 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Sutro Biopharma position peaked at $185K in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.